Publicaciones más recientes

AdnaTest ProstateCancerPanel AR-V7

• Horie S. et al. (2020)
  Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLOS ONE
• Vlaeminck-Guillem V. et al. (2019)
  Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. European Urology Oncology
• Cappelletti V. et al. (2019)
  Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cáncer
• Clark E. et al. (2019)
  Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ
• Antonarakis E. et al. (2019)
  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol
• Hench I. et al. (2019)
  Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cáncer
• Zhang T. et al. (2019)
  The Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. ScienceDirect 
• Josefsson A. et al. (2018)
  Circulating tumor cells mirror bone metastatic phenotype in prostate cancer. Oncotarget